A medication that has been around for decades and used to treat several conditions, including a chronic parasitic infection, is now emerging as a potential option for patients with a different and far rarer disease. Early findings suggest the drug could help people with Bachmann-Bupp syndrome (BABS), a life-threatening genetic disorder that affects only a small number of individuals worldwide. This progress is being driven by a new collaboration between Corewell Health, Michigan State University, and Every Cure, a nonprofit biotech group focused on finding new uses for existing drugs. "Beyond helping us build preclinical studies and retrospective analyses, the team at Every Cure has already begun helping us navigate regulatory pathways and compliance on so many levels in the hopes that we can treat more of our BABS patients," said Caleb Bupp, M.D., pediatric geneticist for Corewell Health Helen DeVos Children's Hospital in Grand Rapids, Michigan.…